Table 1. Phase III studies of anti-PD-1 or PD-L1 mAbs in aNSCLC with subgroup analysis data in the elderly population.
| Author (year) | Study | Phase | Histology | Line | Treatment arms | No. of patients | Median age (years) | Age cut-off, older patients | No. of older [%] | Overall survivals | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall HR (95% CI) | HR for younger (95% CI) | HR for older (95% CI) | ||||||||||
| Borghaei (2015) | CheckMate 057 | III | Nonsquamous NSCLC | >1 | Nivo vs. Docetaxel | 582 | 61.0 [37–84]; 64.0 [21–85] | 65–74; ≥75 | 200 [34]; 43 [7] | 0.73 (0.59–0.89) | 0.81 (0.62–1.04) | 0.63 (0.45–0.89); 0.90 (0.43–1.87) |
| Brahmer (2015) | CheckMate 017 | III | Squamous NSCLC | >1 | Nivo vs. Docetaxel | 272 | 62.0 [39–85]; 64 [42–84] | 65–74; ≥75 | 91 [33]; 29 [11] | 0.59 (0.44–0.79) | 0.52 (0.35–0.75) | 0.56 (0.34–0.91); 1.85 (0.76–4.51) |
| Carbone (2017) | CheckMate 026 | III | NSCLC | 1 | Nivo vs. PBCh | 423 | 63 [32–89]; 65 [29–87] | ≥65: 65–74; ≥75 | 260 [48]: 198 [37]; 62 [11] | 1.08 (0.87–1.34) | 1.13 (0.83–1.54) | 1.04 (0.77–1.41) |
| Herbst (2016) | Keynote-010 | II/III | NSCLC | >1 | Pembro 2 mg/kg vs. Pembro 10 mg/kg vs. Docetaxel | 1,034 | 63 [56–69]; 63 [56–69]; 62 [56–69] |
≥65 | 429 [41] | 0.71 (0.58–0.88); 0.61 (0.49–0.75) |
0.63 (0.50–0.79); pooled-analysis |
0.76 (0.57–1.02); pooled-analysis |
| Reck (2019) | Keynote-024 | III | NSCLC | 1 | Pembro vs. PBCh | 305 | 64.5 [33–90]; 66.0 [28–85] | ≥65 | 164 [54] | 0.63 (0.47–0.86) | 0.60 (0.38–0.96) | 0.64 (0.42–0.98) |
| Mok (2019) | Keynote-042 | III | NSCLC | 1 | Pembro vs. PBCh | 1,274 | 63.0 [57–69]; 63.0 [57–69] | ≥65 | 567 [44] | TPS ≥50%: 0.69 (0.56–0.85); TPS ≥20%: 0.77 (0.64–0.92); TPS ≥1%: 0.81 (0.71–0.93) | 0.81 (0.60–1.08); 0.84 (0.65–1.08); 0.81 (0.67–0.98) |
0.58 (0.42–0.80); 0.71 (0.54–0.92); 0.82 (0.66–1.01) |
| Fehrenbacher (2018) | OAK | III | NSCLC | >1 | Atezo vs. Docetaxel | 1,225 | 63.0 [25–84]; 64.0 [34–85] | ≥65 | 564 [46] | 0.80 (0.70–0.92) | 0.84 (0.70–1.01) | 0.75 (0.61–0.91) |
| Spigel (2019) | IMpower-110 | III | NSCLC | 1 | Atezo vs. PBCh | 554 | NA; NA | TC3/IC3, ≥65: 65–74; ≥75 | 103 [50]: 80 [39]; 22 [11] | TC3/IC3: 0.59 (0.40–0.89) | TC3/IC3: 0.59 (0.34–1.04) | TC3/IC3: 0.63 (0.34–1.19); 1.04 (0.19–5.70) |
| Planchard (2020) | ARCTIC Study A | III | NSCLC | >2 | Durva vs. SoC | 126 | 63.5 [35–79]; 62.0 [41–81] | ≥65 | 56 [44] | 0.63 (0.42–0.93) | NA | NA |
| Rizvi (2020) | MYSTIC | III | NSCLC | 1 | Durva vs. Durva + Treme vs. PBCh | TPS ≥25: 489 | 64.0 [32–84]; 65.0 [64–87]; 64.5 [35–85] | ≥65 | 256 [52] | 0.76 (0.56–1.02); 0.85 (0.61–1.17) | 0.86 (0.60–1.24); NA | 0.66 (0.45–0.95); NA |
aNSCLC, advanced non-small cell lung cancer; N, number; HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; Nivo, Nivolumab; PBCh, platinum-based chemotherapy; Pembro, Pembrolizumab; Atezo Atezolizumab; Durva, Durvalumab; SoC, standard of care; Treme, Tremelimumab; NA, not available; TPS, tumor proportion score.